KRAS and familial pancreatic carcinoma: In support of the immunotherapy approach are the findings that pancreatic cancer cells express TAAs such as Wilms' tumor gene 1 (WT1) (75%) [36], mucin 1 (MUC1) (over 85%) [37], human telomerase reverse transcriptase (hTERT) (88%) [38], mutated K-RAS (73%) [38, 39], survivin (77%) [40], carcinoembryonic antigen (CEA) (over 90%) [41], HER-2/neu (61.2%) [42], or p53 (67%) [43] as potential targets for immunotherapy.